

Drug Name: Botox (onabotulinumtoxinA) Date: 9-2017

Drug Name:	Botox (onabotulinumtoxinA)
Prescriber Restrictions:	
Age Restrictions:	
Exclusion Criteria:	
Required Medical Information:	<ul> <li>Patient is being treated for blepharospasm or strabismus or</li> <li>Patient is being treated for dystonia or</li> <li>Patient is being treated for spasticity and has not responded to traditional therapy (e.g. oral antispasmodic agents baclofen, dantrolene) or</li> <li>Patient is being treated for chronic migraine and meets the following criteria:         <ul> <li>≥15 headache days/month lasting ≥4 hours each and</li> <li>Failure of ≥2 prophylactic agents from different drug classes of appropriate dose and duration (≥2 months each) due to inadequate response and/or intolerance and</li> <li>Headaches are not resultant of medication overuse (i.e. rebound headaches)</li> <li>Renewal requests must demonstrate a decrease in ≥7 headache days/month following initiation of therapy OR</li> </ul> </li> <li>Patient is being treated for hyperhidrosis and meets the following criteria:         <ul> <li>Patient is diagnosed with severe axillary hyperhidrosis and</li> <li>Patient has failed a recent trial of aluminum chloride of appropriate dose and duration due to inadequate response and/or intolerance and</li> <li>Patient has failed a recent trial of ≥1 oral anticholinergic of appropriate dose and duration due to inadequate response and/or intolerance and</li> <li>Documentation is provided of inability to perform age-appropriate daily activities and</li> <li>Patient has a Hyperhidrosis Disease Severity Scale (HDSS) score of 3-4 prior to initiation of therapy</li> <li>Renewal requests must demonstrate an improvement of patient's HDSS score by ≥2 following initiation of therapy OR</li> </ul> </li> </ul>



Required Medical	• Patient is being treated for overactive or neurogenic bladder and
Information (continued):	meets the following:
	$\circ$ Patient has >8 urinations/24 hours and
	<ul> <li>Patient has ≥2 urinary incontinence episodes/24 hours and</li> </ul>
	<ul> <li>Patient has failed of ≥3 antimuscarinic agents, one of which must be a long-acting agent, of appropriate dose and duration due to inadequate response and/or intolerance and</li> </ul>
	• Patient is able or willing to self-catheterize and
	• Patient is not prone to urinary tract infections
	Renewal requests must demonstrate a decrease of $\geq 2$ urinary
	incontinence episodes/day following initiation of therapy
Coverage duration:	Blepharospasm, strabismus, dystonia and spasticity: 12 months
	Chronic migraine, hyperhidrosis, and overactive neurogenic
	bladder:
	• Initial: 3 months
	• Renewals: 12 months